The woman, who also had myelogenous leukemia, underwent a novel stem cell transplant method in August 2020 that used umbilical cord blood from a partially matched donor who was naturally resistant to HIV because of a genetic mutation. Physicians also gave the woman blood stem cells from a relative as a temporary defense until the cord blood transplant took effect. More than a year later, researchers have found no sign of HIV in the woman’s blood tests.
The previous two patients believed to be cured of HIV were treated with a bone marrow transplant technique from donors naturally resistant to HIV.
Scientists said the cord blood transplant method creates an opportunity to cure more people of diverse racial backgrounds who have both HIV and cancer, as cord blood is more readily available than stem cells and donors do not need to match as closely, according to the Times.
Researchers presented their findings this week at the Conference on Retroviruses and Opportunistic Infections in Denver.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.